| Rex Daniel Roach Iii, MD | |
|
6554 Lubarrett Way, Mobile, AL 36695-3825 | |
| (251) 533-3221 | |
| Not Available |
| Full Name | Rex Daniel Roach Iii |
|---|---|
| Gender | Male |
| Speciality | Pathology - Anatomic Pathology & Clinical Pathology |
| Location | 6554 Lubarrett Way, Mobile, Alabama |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1922468677 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207ZP0102X | Pathology - Anatomic Pathology & Clinical Pathology | 21974 (Alabama) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Rex Daniel Roach Iii, MD 6554 Lubarrett Way, Mobile, AL 36695-3825 Ph: (251) 533-3221 | Rex Daniel Roach Iii, MD 6554 Lubarrett Way, Mobile, AL 36695-3825 Ph: (251) 533-3221 |
News Archive
According to a recent study published in Rheumatologia, the official journal of the Institute of Rheumatology and the Polish Rheumatological Society, PCSO-524, an all natural, patented, Omega-3 fish oil extract containing DHA and EPA from the New Zealand green-lipped mussel, found in Omega XL, may provide more benefits for joint mobility and pain compared to standard fish oil.
Changes to the communities of microbes living in the reproductive tract of pregnant women could help to spot those at risk of giving birth prematurely.
Among patients with stable cardiovascular disease who have a genetic variation that diminishes the response to the antiplatelet drug clopidogrel, tripling the standard daily dosage of this medication resulted in improved platelet reactivity, according to a study appearing in JAMA.
SanBio Inc. announced today that the United States Food and Drug Administration (FDA) has approved the clinical testing of their SB623 regenerative medicine product in patients suffering from disability caused by cerebral stroke. SB623 is derived from bone marrow stromal cells (MSCs) isolated from healthy adult donors.
Nektar Therapeutics today announced positive preliminary initial results from a two-stage Phase 2 clinical study evaluating single-agent NKTR-102 in women with advanced/metastatic breast cancer patients who have received a prior taxane. The increased use of taxanes in breast cancer often renders tumors resistant to these drugs by the time the disease recurs, thereby underscoring the urgent need for new treatment options with novel mechanisms of action for metastatic disease.
› Verified 3 days ago
Dr. Lloyd Gardner, MD Pathology Medicare: Not Enrolled in Medicare Practice Location: 5 Mobile Infirmary Cir, Mobile, AL 36607 Phone: 251-460-0326 Fax: 251-460-2846 | |
Dr. Lee Fucich, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 5 Mobile Infirmary Cir, Mobile, AL 36607 Phone: 251-460-0326 Fax: 251-460-2846 | |
Elizabeth A. Manci, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 1700 Center St, Pathology, Mobile, AL 36604 Phone: 251-415-1612 Fax: 251-415-1003 | |
Carole Boudreaux, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 2451 Fillingim St, Pathology, Mobile, AL 36617 Phone: 251-471-7790 Fax: 251-471-7715 | |
Jonathan Newsom, Pathology Medicare: Medicare Enrolled Practice Location: 2451 University Hospital Dr, Mobile, AL 36617 Phone: 251-470-9912 | |
Dr. Rodney Edwin Shackelford, DO Pathology Medicare: Medicare Enrolled Practice Location: 2451 University Hospital Dr, Mobile, AL 36617 Phone: 251-471-7790 Fax: 251-471-7096 | |
Eugene Hart, M.D. Pathology Medicare: Not Enrolled in Medicare Practice Location: 2451 Fillingim St, Department Of Pathology, Mobile, AL 36617 Phone: 251-471-7026 |